1 insider bought €13k of shares over the last 90 days, the latest by 김종철, filed 22 Oct 2026.
MEKICS Co., Ltd: what insiders have been doing
MEKICS Co., Ltd belongs to the Health Care sector. Filings by its managers are published through DART (FSS). Over the twelve months to 31 October 2026, 32 filings were filed, from 6 insiders.
On the market, 5 insiders bought (24 purchases totalling €19k) while 1 insider sold (2 sales). The amount is not disclosed for 25 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €19k by 김종철, published on 26 March 2026, equal to 0.11% of the market capitalisation. The buyers include 4 board members and 1 chief executive.
The most recent open-market purchase was published on 22 October 2026, 18 days ago. The median gap between trade and publication is zero days: most filings appear on the same day. That lag is the time during which only the insider knows about the trade.
With 32 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. The full history, which starts in 2021, counts 43 purchases against 4 sales.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -50.9%Entry ₩2,890 · Close 30 Oct 2026 ₩1,420
- -55.8%Entry ₩3,210 · Close 30 Oct 2026 ₩1,420
- -30.7%Entry ₩2,050 · Close 30 Oct 2026 ₩1,420
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 13,260 sharesShareKRXDART:20261022000020Canonical exit: 20 Jan 2027 (T+90)
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 1 sharesShareKRXDART:20260724000267Canonical exit: 22 Oct 2026 (T+90)
- 1,000 sharesShareKRXDART:20260616000065Canonical exit: 14 Sept 2026 (T+90)
- 1,000 sharesShareKRXDART:20260612000515Canonical exit: 10 Sept 2026 (T+90)
- 1,000 sharesShareKRXDART:20260611000468Canonical exit: 9 Sept 2026 (T+90)
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- 500 sharesShareKRXDART:20260427000673Canonical exit: 15 Jul 2026 (T+90)
- 1,000 sharesShareKRXDART:20260414001400Canonical exit: 9 Jul 2026 (T+90)
- 1,000 sharesShareKRXDART:20260408002524Canonical exit: 6 Jul 2026 (T+90)
- 500 sharesShareKRXDART:20260403001086Canonical exit: 30 Jun 2026 (T+90)
- 500 sharesShareKRXDART:20260331003336Canonical exit: 29 Jun 2026 (T+90)
- 500 sharesShareKRXDART:20260330001272Canonical exit: 28 Jun 2026 (T+90)
- 500 sharesShareKRXDART:20260327000388Canonical exit: 25 Jun 2026 (T+90)
- 15,936 shares0.11% mcap100.0% of flowKRXDART:20260326001304Canonical exit: 16 Jun 2026 (T+90)
- 500 sharesShareKRXDART:20260326001241Canonical exit: 24 Jun 2026 (T+90)
25 of 75 declarations
About MEKICS Co., Ltd
멕아이씨에스 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX. It specializes in developing innovative solutions for the medical field.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
